Success Metrics

Clinical Success Rate
60.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(40%)

Phase Distribution

Ph phase_1
2
40%
Ph phase_2
3
60%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Terminated(2)

Detailed Status

Completed3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
60.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

completed360%
terminated240%

Recent Activity

0 active trials
Showing 5 of 5
terminatedphase_2

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT06237309
terminatedphase_2

REGN5381 in Adult Participants With Uncontrolled Hypertension

NCT06833190
completedphase_2

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

NCT05353166
completedphase_1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

NCT05291546
completedphase_1

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

NCT04506645

Clinical Trials (5)

Showing 5 of 5 trials
NCT06237309Phase 2

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

Terminated
NCT06833190Phase 2

REGN5381 in Adult Participants With Uncontrolled Hypertension

Terminated
NCT05353166Phase 2

REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure

Completed
NCT05291546Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants

Completed
NCT04506645Phase 1

Study to Assess the Safety, Tolerability, and Pharmacokinetics of REGN5381 (an NPR1 Agonist) in Adult Humans

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5